Tear test: new study probes how dry eye drug alters eye proteins

NCT ID NCT07490535

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study will measure changes in tear fluid proteins in 36 adults with dry eye disease who are already using lifitegrast (Xiidra) eye drops. Researchers want to see how the drug affects these biomarkers over 84 days. The goal is to better understand dry eye and how the treatment works, not to test a new cure.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OCULAR SURFACE DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

dry eye syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Pittsburgh Research Institute

    Sewickley, Pennsylvania, 15143, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact